![]() Ardelyx Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders. | |||
Founding Date | Founding Date 2014 | Founding Date 2007 | Founding Date 2016 |
Type | Type Private | Type Public | Type Private |
Tags | |||
Locations | Locations Oxford, GB HQ Cambridge, GB Cambridge, US | Locations Fremont, US HQ Waltham, US Waltham, US | Locations Tübingen, DE HQ Tübingen, DE |
Employees | Employees 1804% increase | Employees 882% increase | Employees 15 |
Financial | |||
Revenue (est.) | Revenue (est.) £2.8m (FY, 2019) | Revenue (est.) $407.3m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income (£2.5m) (FY, 2019) | Net income ($61.6m) (FY, 2025) | Net income N/A |
Funding | |||
Latest funding round | Latest funding round $ 10.2m (over 7 years ago) | Latest funding round N/A | Latest funding round $ 12.2m (over 6 years ago) |
Total funding raised | Total funding raised $ 61.9m | Total funding raised $ 61.1m | Total funding raised $ 21.2m |

Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
View company